Shares in Acorda Therapeutics (NSDQ:ACOR) jumped this morning after the company reported that its inhaled Parkinson’s drug significantly improved motor function in a Phase III trial.
The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms.
The Phase III Span-Pd trial enrolled 339 patients with Parkinson’s disease and found that 84 milligrams of CVT-301 improved motor function compared to placebo, measured at 30 minutes post-dose after 12 weeks.
Get the full story at our sister site, Drug Delivery Business News.